Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer

Lung Cancer

Volumn 59, Issue 3, 2008, Pages 364-368

  Lee, Siow Ming ^a   James, Lindsay ^b   Buchler, Tomas ^a   Snee, Mike ^c   Ellis, Paul ^d   Hackshaw, Allan ^b  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

Anti angiogenesis; Carboplatin; Etoposide; Phase II; Small cell lung cancer; Thalidomide

Indexed keywords

CARBOPLATIN; ETOPOSIDE; THALIDOMIDE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DROWSINESS; DRUG DOSE REDUCTION; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; SURVIVAL RATE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 40249114881     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.032     Document Type: Article

References (25)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91 (1997) 4082-4085
3. Kenyon B.M., Browne F., and D'Amato R.J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 64 (1997) 971-978
4. Salven P., Ruotsalainen T., Mattson K., and Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79 (1998) 144-146
5. Ueno K., Inoue Y., Kawaguchi T., Hosoe S., and Kawahara M. Increased serum levels of basic fibroblast growth factor in lung cancer patients: relevance to response of therapy and prognosis. Lung Cancer 31 (2001) 213-219
6. Reyes-Teran G., Sierra-Madero J.G., Martinez del Cerro V., Arroyo-Figueroa H., Pasquetti A., Calva J.J., et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10 (1996) 1501-1507
7. Chlebowski R.T., Palomares M.R., Lillington L., and Grosvenor M. Recent implications of weight loss in lung cancer management. Nutrition 12 Suppl. 2 (1996) S43-S47
8. Haslett P.A. Anti-cytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25 (1998) 53-57
9. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
10. Sleijfer S., Kruit W.H., and Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 40 (2004) 2377-2382
11. Kumar S., Witzig T.E., and Rajkumar S.V. Thalidomide: current role in the treatment of non-plasma cell malignancies. J Clin Oncol 22 (2000) 2477-2488
12. Little R.F., Wyvill K.M., Pluda J.M., Welles L., Marshall V., Figg W.D., et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18 (2000) 2593-2602
13. Ching L.M., Browne W.L., Tchernegovski R., Gregory T., Baguley B.C., and Palmer B.D. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity. Br J Cancer 78 (1998) 336-343
14. Murphy S., Boyle F.M., Davey R.A., Gu X.Q., and Mather L.E. Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol 59 (2007) 105-114
15. Minchinton A.I., Fryer K.H., Wendt K.R., Clow K.A., and Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 7 (1996) 339-343
16. Fine H.A., Wen P.Y., Maher E.A., Viscosi E., Batchelor T., Lakhani N., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21 (2003) 2299-2304
17. Jain R.K. Normalization of tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Natl. Med 7 (2001) 987-989
18. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
19. Willett C.G., Boucher Y., di Tomaso E., Duda D.G., Munn L.L., Tong R.T., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Natl Med 10 (2004) 145-147
20. Souhami R.L., Bradbury I., Geddes D.M., Spiro S.G., Harper P.G., and Tobias J.S. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45 (1985) 2878-2882
21. WHO handbook for reporting results of cancer treatment. World Health Organization: Geneva; 1979.
22. Dowlati A., Subbiah S., Cooney M., Rutherford K., Mekhail T., Fu P., et al. Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer 56 3 (2007) 377-381
23. Pujol J.L., Breton J.L., Gervais R., Tanguy M.L., Quoix E., David P., et al. A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): an intergroup study FNCLCC Cleo04-IFCT 00-01. Proc Am Soc Soc Clin Oncol 24 (2006) 372s
24. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82 (2000) 812-817
25. Riedel R.F., Crawford J., Dunphy F., Herndon II J.E., Garst J., and Kelley M.J. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer 54 (2006) 431-432